AU2021327397A1 - Compounds as glp-1r agonists - Google Patents

Compounds as glp-1r agonists Download PDF

Info

Publication number
AU2021327397A1
AU2021327397A1 AU2021327397A AU2021327397A AU2021327397A1 AU 2021327397 A1 AU2021327397 A1 AU 2021327397A1 AU 2021327397 A AU2021327397 A AU 2021327397A AU 2021327397 A AU2021327397 A AU 2021327397A AU 2021327397 A1 AU2021327397 A1 AU 2021327397A1
Authority
AU
Australia
Prior art keywords
optionally substituted
compound
ring
alkyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021327397A
Other languages
English (en)
Other versions
AU2021327397A9 (en
Inventor
Martijn Fenaux
Christopher T. Jones
Thorsten A. Kirschberg
Corey REEVES
F. Anthony Romero
Yingzi XU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Terns Pharmaceuticals Inc
Original Assignee
Terns Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terns Pharmaceuticals Inc filed Critical Terns Pharmaceuticals Inc
Publication of AU2021327397A1 publication Critical patent/AU2021327397A1/en
Publication of AU2021327397A9 publication Critical patent/AU2021327397A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2021327397A 2020-08-21 2021-08-20 Compounds as glp-1r agonists Pending AU2021327397A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063068870P 2020-08-21 2020-08-21
US63/068,870 2020-08-21
PCT/US2021/047015 WO2022040600A1 (en) 2020-08-21 2021-08-20 Compounds as glp-1r agonists

Publications (2)

Publication Number Publication Date
AU2021327397A1 true AU2021327397A1 (en) 2023-05-04
AU2021327397A9 AU2021327397A9 (en) 2024-08-08

Family

ID=80350630

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021327397A Pending AU2021327397A1 (en) 2020-08-21 2021-08-20 Compounds as glp-1r agonists

Country Status (15)

Country Link
US (2) US20230322744A1 (https=)
EP (1) EP4199919A4 (https=)
JP (1) JP2023538408A (https=)
KR (1) KR20230074486A (https=)
CN (1) CN116507326A (https=)
AU (1) AU2021327397A1 (https=)
BR (1) BR112023003168A2 (https=)
CA (1) CA3192601A1 (https=)
CL (2) CL2023000516A1 (https=)
CO (1) CO2023003322A2 (https=)
IL (1) IL300795A (https=)
MX (1) MX2023002108A (https=)
PE (1) PE20231206A1 (https=)
TW (1) TWI905252B (https=)
WO (1) WO2022040600A1 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4048664A1 (en) 2019-10-25 2022-08-31 Gilead Sciences, Inc. Glp-1r modulating compounds
ES3016132T3 (en) 2020-01-29 2025-05-08 Gilead Sciences Inc Glp-1r modulating compounds
TW202206429A (zh) 2020-04-29 2022-02-16 美商迦舒布魯姆生物有限公司 雜環ｇｌｐ—１促效劑
JP2023537501A (ja) 2020-08-06 2023-09-01 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
EP4204415A4 (en) 2020-08-28 2025-03-26 Gasherbrum Bio, Inc. HETEROCYCLIC GLP-1 AGONISTS
CA3188891A1 (en) 2020-09-01 2022-01-13 Fanglong Yang Fused imidazole derivative, preparation method therefor, and medical use thereof
EP4247804A1 (en) 2020-11-20 2023-09-27 Gilead Sciences, Inc. Polyheterocyclic glp-1 r modulating compounds
CR20230330A (es) * 2021-01-28 2023-11-15 Carmot Therapeutics Inc Agonistas del receptor gpcr, composiciones farmaceuticas que los comprenden y métodos para su uso
WO2022184849A1 (en) * 2021-03-04 2022-09-09 Les Laboratoires Servier Glp-1r agonists, uses and pharmaceutical compositions thereof
WO2022192428A1 (en) * 2021-03-11 2022-09-15 Gilead Sciences, Inc. Glp-1r modulating compounds
EP4304712A1 (en) * 2021-03-11 2024-01-17 Gilead Sciences, Inc. Glp-1r modulating compounds
US20240208952A1 (en) * 2021-03-22 2024-06-27 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Thiophene glp-1 receptor agonist and use thereof
JP7772778B2 (ja) * 2021-03-24 2025-11-18 塩野義製薬株式会社 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物
CN117222631A (zh) * 2021-03-24 2023-12-12 诚益生物(美国)公司 苯基-[1,3]二氧杂环戊烯并[4,5-c]吡啶基-苯基-、苯基-[1,3]二氧杂环戊烯并[4,5-c]吡啶基-杂芳基-或苯基-[1,3]二氧杂环戊烯并[4,5-c]吡啶基-哌啶基-甲基-氧杂环丁烷基甲基-1h-苯并[d]咪唑-甲酸衍生物及其使用方法
IL306110A (en) 2021-04-21 2023-11-01 Gilead Sciences Inc Carboxy-benzimidazole glp-1r modulating compounds
TWI843104B (zh) 2021-05-20 2024-05-21 美商美國禮來大藥廠 類升糖素肽1受體促效劑
WO2023011539A1 (zh) * 2021-08-04 2023-02-09 上海翰森生物医药科技有限公司 环烯类衍生物调节剂、其制备方法和应用
US20240374587A1 (en) 2021-09-08 2024-11-14 Shionogi & Co., Ltd. Medicine for prevention and treatment of diseases linked to anti-obesity activity
PT4408840T (pt) 2021-09-27 2025-10-07 Terns Pharmaceuticals Inc Ácidos benzimidazolocarboxílicos como agonistas de glp-1r
US20250115612A1 (en) 2021-10-05 2025-04-10 Astrazeneca Ab Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4-b]pyrazines as glp-1 receptor modulators
WO2023057414A1 (en) 2021-10-05 2023-04-13 Astrazeneca Ab Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
MX2024004131A (es) 2021-10-05 2024-04-22 Astrazeneca Ab Ciertos 2,5-diazabiciclo[4.2.0]octanos como moduladores del receptor de glp-1.
CN118401519A (zh) 2021-10-25 2024-07-26 拓臻制药公司 作为glp-1r激动剂的化合物
US20250042882A1 (en) 2021-12-16 2025-02-06 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
WO2023111144A1 (en) 2021-12-16 2023-06-22 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
CN119095843A (zh) 2022-02-23 2024-12-06 拓臻制药公司 作为glp-1r激动剂的化合物
US20250214968A1 (en) * 2022-03-25 2025-07-03 Ildong Pharmaceutical Co., Ltd. Novel Salt of GLP-1 Receptor Agonist Compound, Preparation Method Thereof and Pharmaceutical Composition Comprising Thereof
US20250136584A1 (en) * 2022-05-20 2025-05-01 Chengdu Di'ao Jiuhong Pharmaceutical Factory Benzimidazole Or Azabenzimidazole Compound, Preparation Method Therefor And Use Thereof
CN120289354A (zh) * 2022-07-18 2025-07-11 厦门市博瑞来医药科技有限公司 五元并六元化合物、其中间体、制备方法、组合物和应用
JPWO2024063140A1 (https=) * 2022-09-22 2024-03-28
EP4592285A1 (en) 2022-09-22 2025-07-30 Shionogi & Co., Ltd. Fused ring compound having glp-1 receptor agonist effect
CN116102543B (zh) * 2022-10-21 2025-07-22 江南大学 一种glp-1r激动剂、合成方法及其用途
WO2024102625A1 (en) 2022-11-11 2024-05-16 Eli Lilly And Company Glucagon-like peptide 1 receptor agonists
KR20250085816A (ko) 2022-11-16 2025-06-12 일라이 릴리 앤드 캄파니 글루카곤-유사 펩티드 1 수용체 효능제
TW202434574A (zh) * 2023-02-02 2024-09-01 大陸商江蘇豪森藥業集團有限公司 一種環烯類化合物的鹽、晶型及其製備方法和應用
EP4568664B1 (en) 2023-04-07 2026-04-01 Terns Pharmaceuticals, Inc. Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity
WO2024212742A1 (zh) * 2023-04-10 2024-10-17 上海研健新药研发有限公司 一种glp-1r激动剂，其制备方法和应用
CN120981457A (zh) 2023-09-14 2025-11-18 歌礼制药(中国)有限公司 Glp-1r激动剂及其治疗方法
TW202515865A (zh) * 2023-09-21 2025-04-16 南韓商尹諾衛醫藥有限公司 製備取代的稠合咪唑衍生物的方法
TW202521534A (zh) 2023-11-24 2025-06-01 香港商歌禮製藥(中國)有限公司 Glp-1r 激動劑及其治療方法
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102314286B1 (ko) * 2016-12-16 2021-10-21 화이자 인코포레이티드 Glp-1 수용체 작용제 및 이의 용도
DK3806855T5 (da) * 2018-06-15 2023-05-22 Pfizer GLP-1-receptoragonister og anvendelser deraf
US11254660B2 (en) * 2018-08-31 2022-02-22 Pfizer Inc. Combinations for treatment of NASH/NAFLD and related diseases
MA54555A (fr) * 2018-11-22 2021-09-29 Qilu Regor Therapeutics Inc Agonistes de glp-1r et leurs utilisations
WO2021096284A1 (ko) * 2019-11-15 2021-05-20 일동제약(주) Glp-1 수용체 작용제 및 이의 용도
EP4334304A1 (en) * 2021-05-03 2024-03-13 Carmot Therapeutics, Inc. Benzimidazoyl glp-1 receptor agonists, pharmaceutical compositions comprising the same, and methods for their use
CN117715906A (zh) * 2021-07-21 2024-03-15 和博医药有限公司 胰高血糖素样肽-1受体调节剂及其用途

Also Published As

Publication number Publication date
US20230322744A1 (en) 2023-10-12
CO2023003322A2 (es) 2023-07-10
TWI905252B (zh) 2025-11-21
WO2022040600A1 (en) 2022-02-24
AU2021327397A9 (en) 2024-08-08
IL300795A (en) 2023-04-01
KR20230074486A (ko) 2023-05-30
EP4199919A1 (en) 2023-06-28
EP4199919A4 (en) 2024-12-25
JP2023538408A (ja) 2023-09-07
CN116507326A (zh) 2023-07-28
TW202227410A (zh) 2022-07-16
US20220089578A1 (en) 2022-03-24
CL2024001025A1 (es) 2024-10-04
BR112023003168A2 (pt) 2023-05-09
CL2023000516A1 (es) 2023-10-30
CA3192601A1 (en) 2022-02-24
PE20231206A1 (es) 2023-08-17
MX2023002108A (es) 2023-07-11

Similar Documents

Publication Publication Date Title
TWI905252B (zh) 作為glp-1r促效劑之化合物
US10851081B2 (en) GLP-1 receptor agonists and uses thereof
JP6976953B2 (ja) Ｒｏｃｋ阻害剤としてのスピロヘプタンサリチルアミドおよび関連性化合物
CA3216163A1 (en) Carboxy-benzimidazole glp-1r modulating compounds
KR20230173719A (ko) 카르복시-벤즈이미다졸 glp-1r 조절 화합물
EA024123B1 (ru) Тетрагидропиридопиримидиновые производные
CA2962578A1 (en) Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
TW202346289A (zh) 作為ｇｌｐ—１ｒ促效劑的化合物
JP7840334B2 (ja) 芳香族複素環式化合物、薬学的組成物、及びその使用
WO2012101487A1 (en) Di/tri-aza-spiro-c9-c11alkanes
TW202334167A (zh) 作為ｅｒｂｂ２抑制劑之稠合四環喹唑啉衍生物
WO2022233442A1 (en) 2,8-dihydropyrazolo[3,4-b]indole derivatives for use in the treatment of cancer
WO2025170939A1 (en) Proteasome inhibitors for the treatment of malaria
WO2026011019A1 (en) Pyrrolidinyl compounds as inhibitors of cgas
CA3222054A1 (en) 2, 8-diazaspiro[4.5]decane compounds
WO2024220399A1 (en) Pyrazolotriazinecarbonitriles useful as kinase inhibitors
US20260055057A1 (en) Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof
CN121494918A (zh) 具有ret抑制活性的ret降解剂及合成与应用
EP4334319A1 (en) 2,8-dihydropyrazolo[3,4-b]indole derivatives for use in the treatment of cancer

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: ADD THE NAMES OF CO-INVENTORS KIRSCHBERG, THORSTEN A. AND XU, YINGZI

SREP Specification republished